Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRX-818 in advanced solid tumors
NCT02703298Phase 1Completed
- Sponsor
- TaiRx, Inc.
- Start
- Mar 2016
- Primary completion
- Jan 2018
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dasatinib in solid tumor (advanced stage), sponsored by TaiRx, Inc. Primary endpoints: Dose Limiting Toxicity at 28 days and Maximum Tolerated Dose at 28 days. Started Mar 2016; status: completed.
02
Drugs
dasatinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02703298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02703298.